A
Airway Therapeutics
Airway Therapeutics focuses on pulmonary research program of Cincinnati Children’s Hospital Medical Center for further development
About Airway Therapeutics
Airway Therapeutics is a biotechnology company focused on developing novel biologics to address respiratory and inflammatory diseases. The company operates in the healthcare sector, specifically targeting conditions such as bronchopulmonary dysplasia (BPD) and other serious respiratory diseases. Airway Therapeutics' core product, AT-100, is a recombinant human protein engineered to reduce inflammation and infection while modulating the immune response. This product aims to break the cycle of injury and inflammation, offering a potential therapeutic solution for conditions exacerbated by ventilation and infection, particularly in very preterm infants.
Read full description
The company serves a specialized market, primarily targeting healthcare providers, hospitals, and research institutions involved in neonatal and respiratory care. Airway Therapeutics' business model revolves around research and development, clinical trials, and eventual commercialization of its biologic therapies. Revenue generation is expected through product sales, licensing agreements, and potential partnerships with larger pharmaceutical companies.
Airway Therapeutics has secured significant funding through multiple rounds of financing, including Series B and Series C rounds, to advance its preclinical and clinical research programs. The company is also collaborating with organizations like the Celonic Group to produce AT-100, positioning it as a promising candidate for treating novel coronavirus infections.
At a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Cincinnati, United States
- Employees
- 16
- Open positions
- None listed
- Dealroom signal
- 82.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Airway Therapeutics.
Funding history
Company financing events and reported valuations.
Growth signals
Latest recorded traffic for Airway Therapeutics is 1K monthly website visits, up 44.9% over the last three months. Airway Therapeutics's team grew 6.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
CincyTech
Series A3 investors entered at this stage
Cincinnati Children’s Hospital Medical Center
QCA Ventures- DCDanmar Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Airway Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Airway Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.